Industry reports
Editor highlights

Publication dates

All regions

Ovarian Cancer Research Reports, April 2014

You might be interested in: cancer, therapeutics, medical equipment, more »


 

1-20 of about 5 900 reports for Ovarian Cancer
HealthLinx Limited (Symbol:HTX) SWOT Analysis, Strategy, Revenues and Profits

HealthLinx Limited (Symbol:HTX) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • April 2014
  • by Global Data

... And diagnostic products. Its products include cr0014, ovplex, and clear it. Healthlinx's cr014 is an inhibitor of vascular leak; ovplex is a multimarker blood test for ovarian cancer; and clear it is a protein ...

Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014

Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014

  • $ 2 500
  • Industry report
  • April 2014
  • by Global Data

... To the clinical trials on metastatic ovarian cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary ...

Ovarian Cancer Drug Pipeline Update 2014

Ovarian Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

... There are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 94 drugs. ovarian cancer drug pipeline update lists all drugs and gives you a progress analysis ...

Ovarian Cancer Drug Pathway Analyzer 2014

Ovarian Cancer Drug Pathway Analyzer 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

... Specifications3. Compare - you can overlay any pathways with each other and do a comparative analysisyou can interactively analyze any ovarian cancer drug-pathway relationship by using up to four ...

Sanofi (SAN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Sanofi (SAN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • March 2014
  • by Global Data

... Institut curie enters into research agreement with sanofi to develop ovarian cancer treatments 85nextbio enters into agreement with sanofi for translational medicine 87takeda pharma enters into co ...

Ovarian Cancer Partnering 2009-2014

Ovarian Cancer Partnering 2009-2014

  • $ 995
  • Industry report
  • March 2014
  • by Currentpartnering

... Report contains over 75 links to online copies of actual ovarian cancer deals and contract documents as submitted to the securities exchange commission by companies and their partners, where available ...

Epithelial Ovarian Cancer - Pipeline Review, H1 2014

Epithelial Ovarian Cancer - Pipeline Review, H1 2014

  • $ 2 000
  • Industry report
  • February 2014
  • by Global Markets Direct

... ovarian cancer pipeline on the basis of target, moa, route of administration and molecule type- latest news and deals relating related to pipeline productsreasons to buy- provides ...

Drug and Medication Industry: Fallopian Tube Cancer – Pipeline Review, H1 2012

Drug and Medication Industry: Fallopian Tube Cancer – Pipeline Review, H1 2012

  • $ 2 000
  • Industry report
  • February 2014
  • by Global Markets Direct

... To present clinical data of ramucirumab at asco 2012 218nov 01, 2010: synta announces gynecologic oncology group to initiate phase ii clinical trial of elesclomol for treatment of ovarian cancer 219 ...

Genisphere Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Genisphere Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Industry report
  • February 2014
  • by Global Data

... For the ultra-sensitive detection of nucleic acids and proteins. Genisphere's therapeutic areas include pancreatic cancer, ovarian cancer, prostate cancer and posterior capsular opacification. The company ...

Vaxeal Holding SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Vaxeal Holding SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • February 2014
  • by Global Data

... Colorectal, breast and ovarian cancer; metastatic melanoma; and hepatitis cgen. Its pipeline products in lead optimization and pre-clinical stage include svx-1, cbx-1 and mdx-1. Vaxeal group is headquartered ...

» View Public Reports

About 100 reports for Ovarian Cancer

» Read our Company Profiles

1 Companies for Ovarian Cancer

GlaxoSmithKline P.L.C.

United States

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.